Kirsten R. Bergmann

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale.

Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 31, 2023

Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers.

Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers.

Journal: The Journal of pharmacology and experimental therapeutics

Published: January 18, 2023

OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.

OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.

Journal: Clinical pharmacology and therapeutics

Published: October 13, 2021

Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations.

Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations.

Journal: British journal of clinical pharmacology

Published: March 22, 2021

Theoretical Performance of Nonlinear Mixed-Effect Models Incorporating Saliva as an Alternative Sampling Matrix for Therapeutic Drug Monitoring in Pediatrics: A Simulation Study.

Theoretical Performance of Nonlinear Mixed-Effect Models Incorporating Saliva as an Alternative Sampling Matrix for Therapeutic Drug Monitoring in Pediatrics: A Simulation Study.

Journal: Therapeutic drug monitoring

Published: February 17, 2021

Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers.

Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers.

Journal: European journal of clinical pharmacology

Published: December 18, 2020

A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.

A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.

Journal: Pharmacology research & perspectives

Published: December 07, 2020

First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management.

First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management.

Journal: British journal of clinical pharmacology

Published: November 01, 2020

Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine.

Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: June 25, 2020

First Clinical Study with AP30663 - a KCa 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation.

First Clinical Study with AP30663 - a KCa 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation.

Journal: Clinical and translational science

Published: February 26, 2020

Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model.

Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: November 20, 2019

Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease.

Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: November 19, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026